An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma

Inclusion Criteria:

- adult patients, >=18 years of age

- relapsed CD20+ indolent B-cell non-Hodgkin's lymphoma

- documented history of response of >/= 6 months duration from last
rituximab-containing regimen

- clinical indication for treatment as determined by the investigator

- ECOG performance status 0-2

Exclusion Criteria:

- prior use of any investigational monoclonal antibody within 6 months of study start

- prior use of any anti-cancer vaccine

- prior use of rituximab within 8 weeks of study entry

- radioimmunotherapy within 3 months prior to study entry

- CNS lymphoma or evidence of transformation to high-grade or diffuse large B-cell
lymphoma